Budesonide

Specifications / Handling

More Information
Product Details
Synonyms	16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
Product Type	Chemical
Properties
Formula	C₂₅H₃₄O₆
MW	430.5
CAS	51333-22-3
RTECS	TU3723000
Purity Chemicals	≥98% (HPLC)
Appearance	White to off-white powder.
Solubility	Soluble in DMSO (25mg/ml), DMF (20mg/ml) or ethanol (10mg/ml).
Identity	Determined by ¹H-NMR.
InChi Key	VOVIALXJUBGFJZ-KWVAZRHASA-N
Smiles	O=C(CO)[C@]12[C@@]3(C)C[C@H](O)[C@@]4([H])[C@@]([C@]3([H])C[C@H]1OC(CCC)O2)([H])CCC5=CC(C=C[C@@]54C)=O
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Budesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC₅₀=45.7pM in a transactivation assay), selective for glucocorticoid over mineralocorticoid receptors.
Budesonide is a synthetic anti-inflammatory agent that displays chemopreventive activity. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis and inflammatory bowel disease and is evaluated in prevention of lung cancer. It prevents formation of lung adenomas and adenocarcinomas in mice following inhalation or oral administration. It also reverses DNA hypomethylation and modulates expression of cancer related genes.
Due to its potent activity, as an inhaled glucocorticoid, in reducing airway inflammation, Budesonide has potential as treatment for early COVID-19 infection. In vitro studies have shown that inhaled glucocorticoids can reduce the replication of SARS-CoV-2 in airway epithelial cells and downregulate the expression of ACE2 and TMPRSS2 genes, which are critical for viral cell entry.
Budesonide in combination with glycopyrronium and formoterol has been shown to inhibit viral replication of the coronavirus HCoV-229E, by inhibiting receptor expression and/or endosomal function.

Product References

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease: C.M. Spencer & D. McTavish; Drugs 50, 854 (1995)
Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: A comparison of their glucocorticoid and mineralocorticoid properties: C. Grossmann, et al.; Eur. J. Endocrinol. 151, 397 (2004)
IκB kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma: M.A. Birrell, et al.; Am. J. Respir. Crit. Care Med. 172, 962 (2005)
Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors: M.A. Pereira, et al.; Int. J. Cancer 120, 1150 (2006)
Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice: L.W. Wattenberg, et al.; Cancer Res. 57, 5489 (2007)
Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma: D.S. Millan, et al.; Bioorg. Med. Chem. Lett. 21, 5826 (2011)
Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells: M. Yamaya, et al.; Respir. Investig. 58, 155 (2020)
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial: S. Ramakrishnan, et al.; Lancet Respir. Med. (Epub ahead of print) (2021)
Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19: A. Agusti, et al.; Lancet Repir. Med. (Epub ahead of print) (2021)

Call	+41 61 926 6040
Fax	+41 61 926 6049